|
1
|
Imamura Y, Morikawa T, Liao X, Lochhead P,
Kuchiba A, Yamauchi M, Qian ZR, Nishihara R, Meyerhardt JA, Haigis
KM, et al: Specific mutations in KRAS codons 12 and 13, and patient
prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer
Res. 18:4753–4763. 2012.PubMed/NCBI
|
|
2
|
Xiao W, Zhao H, Dong W, Li Q, Zhu J, Li G,
Zhang S and Ye M: Quantitative detection of methylated NDRG4 gene
as a candidate biomarker for diagnosis of colorectal cancer. Oncol
Lett. 9:1383–1387. 2015.PubMed/NCBI
|
|
3
|
Luo SL, Hu RY, Gong WW, Wang H, Pan J, Fei
FR and Yu M: Survival rate of colorectal cancer patients during
2005–2010 in Zhejiang province, China. Zhonghua Liu Xing Bing Xue
Za Zhi. 34:1194–1197. 2013.(In Chinese). PubMed/NCBI
|
|
4
|
Song LL and Li YM: Current noninvasive
tests for colorectal cancer screening: An overview of colorectal
cancer screening tests. World J Gastrointest Oncol. 8:793–800.
2016.PubMed/NCBI
|
|
5
|
Iannone A, Losurdo G, Pricci M, Girardi B,
Massaro A, Principi M, Barone M, Ierardi E and Di Leo A: Stool
investigations for colorectal cancer screening: From occult blood
test to DNA analysis. J Gastrointest Cancer. 47:143–151.
2016.PubMed/NCBI
|
|
6
|
Ahlquist DA, Harrington JJ, Burgart LJ and
Roche PC: Morphometric analysis of the ‘mucocellular layer’
overlying colorectal cancer and normal mucosa: Relevance to
exfoliation and stool screening. Hum Pathol. 31:51–57.
2000.PubMed/NCBI
|
|
7
|
Brenner H, Hoffmeister M, Arndt V,
Stegmaier C, Altenhofen L and Haug U: Protection from right- and
left-sided colorectal neoplasms after colonoscopy: Population-based
study. J Natl Cancer Inst. 102:89–95. 2010.PubMed/NCBI
|
|
8
|
Lu H, Huang S, Zhang X, Wang D, Zhang X,
Yuan X, Zhang Q and Huang Z: DNA methylation analysis of SFRP2,
GATA4/5, NDRG4 and VIM for the detection of colorectal cancer in
fecal DNA. Oncol Lett. 8:1751–1756. 2014.PubMed/NCBI
|
|
9
|
Renaud S, Guerrera F, Seitlinger J,
Costardi L, Schaeffer M, Romain B, Mossetti C, Claire-Voegeli A,
Filosso PL, Legrain M, et al: KRAS exon 2 codon 13 mutation is
associated with a better prognosis than codon 12 mutation following
lung metastasectomy in colorectal cancer. Oncotarget. 8:2514–2524.
2017.PubMed/NCBI
|
|
10
|
Ross JP, Rand KN and Molloy PL:
Hypomethylation of repeated DNA sequences in cancer. Epigenomics.
2:245–269. 2010.PubMed/NCBI
|
|
11
|
Rasmussen SL, Krarup HB, Sunesen KG,
Pedersen IS, Madsen PH and Thorlacius-Ussing O: Hypermethylated DNA
as a biomarker for colorectal cancer: A systematic review.
Colorectal Dis. 18:549–561. 2016.PubMed/NCBI
|
|
12
|
Zou H, Harrington JJ, Shire AM, Rego RL,
Wang L, Campbell ME, Oberg AL and Ahlquist DA: Highly methylated
genes in colorectal neoplasia: Implications for screening. Cancer
Epidemiol Biomarkers Prev. 16:2686–2696. 2007.PubMed/NCBI
|
|
13
|
Hinoue T, Weisenberger DJ, Lange CP, Shen
H, Byun HM, Van Den Berg D, Malik S, Pan F, Noushmehr H, van Dijk
CM, et al: Genome-scale analysis of aberrant DNA methylation in
colorectal cancer. Genome Res. 22:271–282. 2012.PubMed/NCBI
|
|
14
|
Mitchell SM, Ross JP, Drew HR, Ho T, Brown
GS, Saunders NF, Duesing KR, Buckley MJ, Dunne R, Beetson I, et al:
A panel of genes methylated with high frequency in colorectal
cancer. BMC Cancer. 14:542014.PubMed/NCBI
|
|
15
|
Melotte V, Lentjes MH, van den Bosch SM,
Hellebrekers DM, de Hoon JP, Wouters KA, Daenen KL,
Partouns-Hendriks IE, Stessels F, Louwagie J, et al: N-Myc
downstream-regulated gene 4 (NDRG4): A candidate tumor suppressor
gene and potential biomarker for colorectal cancer. J Natl Cancer
Inst. 101:916–927. 2009.PubMed/NCBI
|
|
16
|
Park H, Kim Y, Lim Y, Han I and Oh ES:
Syndecan-2 mediates adhesion and proliferation of colon carcinoma
cells. J Biol Chem. 277:29730–29736. 2002.PubMed/NCBI
|
|
17
|
Glöckner SC, Dhir M, Yi JM, McGarvey KE,
Van Neste L, Louwagie J, Chan TA, Kleeberger W, de Bruïne AP, Smits
KM, et al: Methylation of TFPI2 in stool DNA: A potential novel
biomarker for the detection of colorectal cancer. Cancer Res.
69:4691–4699. 2009.PubMed/NCBI
|
|
18
|
Oh TJ, Oh HI, Seo YY, Jeong D, Kim C, Kang
HW, Han YD, Chung HC, Kim NK and An S: Feasibility of quantifying
SDC2 methylation in stool DNA for early detection of colorectal
cancer. Clin Epigenetics. 9:1262017.PubMed/NCBI
|
|
19
|
Lao VV and Grady WM: Epigenetics and
colorectal cancer. Nat Rev Gastroenterol Hepatol. 8:686–700.
2011.PubMed/NCBI
|
|
20
|
Gerecke C, Scholtka B, Löwenstein Y, Fait
I, Gottschalk U, Rogoll D, Melcher R, Kleuser B, et al:
Hypermethylation of ITGA4, TFPI2 and VIMENTIN promoters is
increased in inflamed colon tissue: Putative risk markers for
colitis-associated cancer. J Cancer Res Clin Oncol. 141:2097–2107.
2015.PubMed/NCBI
|
|
21
|
Kadiyska T and Nossikoff A: Stool DNA
methylation assays in colorectal cancer screening. World J
Gastroenterol. 21:10057–10061. 2015.PubMed/NCBI
|
|
22
|
Zou H, Taylor WR, Harrington JJ, Hussain
FT, Cao X, Loprinzi CL, Levine TR, Rex DK, Ahnen D, Knigge KL, et
al: High detection rates of colorectal neoplasia by stool DNA
testing with a novel digital melt curve assay. Gastroenterology.
136:459–470. 2009.PubMed/NCBI
|
|
23
|
Ahlquist DA, Zou H, Domanico M, Mahoney
DW, Yab TC, Taylor WR, Butz ML, Thibodeau SN, Rabeneck L, Paszat
LF, et al: Next-generation stool DNA test accurately detects
colorectal cancer and large adenomas. Gastroenterology.
142:248–256. 2012.PubMed/NCBI
|
|
24
|
Green MR and Sambrook J: Hot start
polymerase chain reaction (PCR). Cold Spring Harb Protoc.
2018:2018.
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI
|
|
26
|
Jiang X, Harrington JJ, Mahoney DW, Oberg
AL, Devens ME, Simonson J, Ahlquist DA and Zou H: T1102 detection
of colorectal neoplasia by stool DNA testing: High discrimination
with multi-marker quantitation. Gastroenterology. 134 (Suppl
1):A–484. 2008.
|
|
27
|
Huang Z, Li L and Wang J: Hypermethylation
of SFRP2 as a potential marker for stool-based detection of
colorectal cancer and precancerous lesions. Dig Dis Sci.
52:2287–2291. 2007.PubMed/NCBI
|
|
28
|
Baek YH, Chang E, Kim YJ, Kim BK, Sohn JH
and Park DI: Stool methylation-specific polymerase chain reaction
assay for the detection of colorectal neoplasia in Korean patients.
Dis Colon Rectum. 52:1452–1459. 2009.PubMed/NCBI
|
|
29
|
Bleeker WA, Hayes VM, Karrenbeld A,
Hofstra RM, Hermans J, Buys CC and Plukker JT: Impact of KRAS and
TP53 mutations on survival in patients with left- and right-sided
Dukes' C colon cancer. Am J Gastroenterol. 95:2953–2957.
2000.PubMed/NCBI
|
|
30
|
Zauber AG: The impact of screening on
colorectal cancer mortality and incidence: Has it really made a
difference? Dig Dis Sci. 60:681–691. 2015.PubMed/NCBI
|
|
31
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI
|
|
32
|
Yang D, Hillman SL, Harris AM, Sinicrope
PS, Devens ME and Ahlquist DA: Patient perceptions of stool DNA
testing for pan-digestive cancer screening: A survey questionnaire.
World J Gastroenterol. 20:4972–4979. 2014.PubMed/NCBI
|
